Biosimilar Red Tape Elimination Act

# Biosimilar Red Tape Elimination Act Summary **What the Bill Would Do:** This bill aims to reduce regulatory requirements for biosimilar medications—drugs designed to be nearly identical copies of existing biologic drugs. Currently, biosimilars must go through an extensive FDA approval process to demonstrate they're equivalent to the original drug. This bill would streamline that process by reducing some of the testing and documentation requirements companies must complete before bringing a biosimilar to market. **Who It Affects:** The bill would primarily affect pharmaceutical companies that develop biosimilar drugs, patients who use biologic medications, and the healthcare system more broadly.

Supporters argue that faster biosimilar approval could increase competition, lower drug prices, and give patients more treatment options. Those with concerns worry that reducing regulatory scrutiny could compromise drug safety and efficacy. **Current Status:** The bill is currently in committee, meaning it hasn't yet been debated or voted on by the full Senate. It was introduced by Senator Mike Lee (R-UT) in the 119th Congress.